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High prevalence rates of type 2 diabetes are being observed in native Canadian communities. It is believed that native populations
haveahigherprevalencerateofvascularcomplicationsthannonnatives.TheSouthernAlbertaStudyofDiabeticRetinopathy(DR)
examined the prevalence and incidence of DR and associated metabolic abnormalities in native and nonnative subjects. Prevalence
rates of DR in type 2 diabetic native and nonnative subjects were identical, with a prevalence rate of 40%. Native subjects with
retinopathy, however, tended to have more advanced changes of retinopathy compared to the nonnative subjects. Key factors such
as A1c, blood pressure, duration of diabetes, and lipid values were not signiﬁcantly diﬀerent between the two cohorts. These
data indicate that ethnicity does play a role in the development and severity of DR but potential risk factors that may aﬀect the
development of retinopathy are not signiﬁcantly diﬀerent between native and nonnative groups.
Copyright © 2007 Stuart A. Ross et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Diabetic retinopathy remains an important cause of visual
loss in persons with diabetes. As the prevalence rates of dia-
betes increase in both the native and nonnative populations,
there is increasing concern of the potential increased num-
bers of patients at risk for diabetic retinopathy. Some poten-
tial risk factors for retinopathy include: A1c, BP (systolic and
diastolic), and duration of diabetes [1–5]. Lipid abnormali-
ties may also play part in the development of retinal changes
[6].
It is often assumed that native populations have diﬀer-
ent prevalence rates of speciﬁc vascular complications and
of the risk factors that may lead to the development of vas-
cular complications. This paper reviews the prevalence rates
of diabetic retinopathy in native and nonnative communities
and directly compares the prevalence rates of potential risk
factors for the development of diabetic retinopathy in these
communities.
2. METHODOLOGY
The Southern Alberta Study of Diabetic Retinopathy
(SASDR) was designed to provide assessment of the preva-
lence and incidence of diabetic retinopathy and other dia-
betes vascular complications and to assess potential risk fac-
tors for the development of retinopathy in a population of
subjects with diabetes. Native and nonnative communities
were assessed as part of the study. The study was carried out
in southern Alberta and included both urban and rural ar-
eas and native reserves. At a minimum of three years follow-
ing the completion of the initial prevalence study, all sub-
jects were invited to take part in the incidence study, which
repeated all parameters of the prevalence programme. This
paper will review only the prevalence data.
All subjects were identiﬁed as either urban (Calgary) or
rural, by the postal codes associated to their place of primary
residence. Within the borders of the study area, there are six
native reserves belonging to Treaty Seven, including the two
largest native reserves in Canada, the Blood and Blackfoot
reserves. The project was approved by (The Conjoint Health
Research Ethics Board, University of Calgary, Canada) and
by the medical committees of each of the native reserves. All
southern Alberta reserves were represented in the study and
are shown in Table 1.
2.1. Recruitment
Insulin-usingsubjects
Registration centers were established across the study area
of southern Alberta. These included all pharmacies, physi-
cians’ oﬃces, nursing homes, auxiliary hospitals, native re-
serves and prisons. Each recruitment site had information
and registration packages and staﬀ was individually trained
to administer the package to all subjects who used insulin.
noninsulin-usingsubjects
The same techniques of registration could not be used for
the noninsulin-using subjects as many may not use drugs2 Experimental Diabetes Research








or have the need to go into a pharmacy. Recruitment of
the noninsulin-using subjects began after the identiﬁcation
of the insulin-using subjects. The family physician of each
insulin-using subject registered in the study was provided
with the number of insulin users registered from their prac-
tice and requested to invite the next and subsequent patients
with noninsulin-using diabetes within the practice, to reg-
ister for the study. Each recruitment site that had recruited
insulin-using subjects was similarly asked to recruit an equal
number of noninsulin-using subjects.
Nonparticipants
Ateachoftherecruitmentsites,ifthediabeticsubjectrefused
to complete the registration card, the gender, approximate
age of the subject, and the speciﬁc reason for the refusal was
documented.
2.2. Assessment
Assessment of the individual subjects was undertaken in
multiplesites.ForthosewholivedinCalgary,participantsat-
tended the central SASDR oﬃce at the University of Calgary.
For those who could not attend in Calgary, remote sites were
set up across southern Alberta. At regular intervals, a mobile
van was utilized to carry the staﬀ and retinal and blood sam-
pling equipment to the sites. Subjects were asked to complete
an extensive 20-page questionnaire which included a review
of ethnic origin, family, and personal medical history with a
specialemphasisonthehistoryofdiabetes, dataofdiagnosis,
drug treatments, and existing vascular complications. A ba-
sic examination was performed, including height and weight
forcalculationofBMI;systolicbloodpressure(BP-S)anddi-
astolic blood pressure (BP-D). Each subject was also asked to
provide a timed-overnight urine sample and a venous blood
sample. Type 2 insulin-using subjects were identiﬁed by a
serum C-peptide > 0.05nmol/L.
Ophthalmologyassessment
Each subject had a complete ophthalmology assessment in-
cluding visual acuity, examination for cataracts, seven-ﬁeld
stereofundus retinal photography, and a slit lamp examina-
tion. The photographic slides were coded and forwarded to
(Wisconsin Eye Reading Center, Wis, USA) for the classiﬁ-
cation of the degree of diabetic retinopathy according to the
Airlie House classiﬁcation as adapted by R. Klein et al. [7]
(see Table 2).
Table 2: Retinal grade classiﬁcation.
Grade Description
10–14 No retinopathy
15–21 Microaneurysms or soft
exudates or retinal hemorrhages
31
Micro aneurysms with any of: venous loops;
soft exudates; intraretinal microvascular abnormalities
(IRMA); venous beading; retinal hemorrhages
41 Microaneurysms with any of the following:
hemorrhages and 4-5 ﬁelds; IRMA 1–3 ﬁelds
51
Microaneurysms with one or more of the following:
hemorrhages and microaneurysms in 4-5 ﬁelds;
IRMA in 4 or more ﬁelds; venous beading in 2
or more ﬁelds
60 Fibrous proliferations
61 Scars of photocoagulation but no evidence of 60 or 65
65 Proliferative retinopathy
Laboratoryinvestigations
Avenous blood sample wasobtained forthe measurementof
anonfastinglipidproﬁle;A1c;serumcreatinine;glucose;and
serum C-peptide (for assessment of insulin-dependency).
Theurinesamplewasassessedforthepresenceofmicroalbu-
minuria and for the presence of ketones. The microalbumin-
excretion rate was measured from a timed-overnight urine
sample.
Statisticalanalysis
To describe the association of ethnicity with retinopathy and
potential risk factors, chi-squared tests were used to compare
rates and t-tests were used to compare means. All testing was




There were a total of 2247 patients with Type 2 diabetes, 232
were native and 2015 were nonnative. Table 3 describes the
breakdown of patients by ethnicity and retinopathy as fol-
lows.
The results of a Chi-Squared test for the equality of the
retinopathy rates, (χ2 = 0.0005 with 1 degree of freedom,
P = .98) indicate that ethnicity appears to play no role on the
incidence of retinopathy for patients with Type 2 diabetes.
The question of whether ethnicity is related to the degree
of retinopathy is described in Table 4 as follows.
The Chi-Square test for independence (χ2 = 13.52 with 2
degrees of freedom, P = .0002) indicates that there is a strong
relationship between ethnicity and the degree of retinopathy
for patients with Type 2 diabetes. If the patient is native thereStuart A. Ross et al. 3
Table 3: Prevalence of diabetic retinopathy.
Native Nonnative Total
No retinopathy 137 (60%) 1208 (60%) 1345 (60%)
retinopathy 91 (40%) 805 (40%) 895 (40%)
Total 228 (100%) 2013 (100%) 2241(100%)
Table 4: Degree of retinopathy.
Native Nonnative Total
Background 45 (49%) 551 (68%) 596 (67%)
Preproliferative 33 (36%) 174 (22%) 207 (23%)
Proliferative 13 (14%) 80 (10%) 93 (10%)
Total 91 (100%) 805 (100%) 896 (100%)
is a good chance that his/her retinopathy will be more severe
than if the patient was nonnative.
Riskfactorsforretinopathy
Table 5 provides a breakdown of these factors relative to na-
tive/nonnative classiﬁcations as follows.
The native subjects had poorer glucose control with sig-
niﬁcantly higher levels of A1c compared to the nonnative
subjects.Thereweresmallbutsigniﬁcantdiﬀerencesbetween
native and nonnative subjects in measurements of diastolic
blood pressure. Native subjects showed signiﬁcantly better
lipidproﬁlescomparedtothenonnative subjects.Therewere
no signiﬁcant diﬀerences in systolic blood pressure measure-
ments or duration of diabetes between the two groups.
Tables 6–9 investigate the risk factors with degree of
retinopathy. Each table is broken down by the risk factor and
native/nonnative categories. Ret 1 is no retinopathy; Ret 2 is
background retinopathy; Ret 3 is preproliferative retinopa-
thy; and Ret 4 is proliferative retinopathy.
Native subjects had signiﬁcantly higher A1c values with
minor diﬀerences in the other parameters (see Table 6).
Native subjects had signiﬁcantly higher BP-D; HDL-C
values; and shorter duration of diabetes (see Table 7).
There were no clinically signiﬁcant diﬀerences between
the native and nonnative groups apart from signiﬁcantly
higher HDL-C values in native subjects (see Table 8).
While the mean values in the native group for A1c, blood
pressure readings, lipids, and duration are higher than the
nonnative groups, there were no signiﬁcant diﬀerences be-
tween the two subject groups (see Table 9).
The most frequent diﬀerences in risk factors between na-
tive and nonnatives are at the “no retinopathy” stage and the
“background” stage. Once a patient has preproliferative or
proliferativedisease,thereisverylittleornodiﬀerenceinrisk
factors regardless of ethnicity.
4. DISCUSSION
The prevalence of diabetes is increasing worldwide. Associ-
ated with this increase is an increased risk of development
of micro- and macrovascular complications including dia-
betic retinopathy. Aboriginal or native communities may be
atincreased risk ofdeveloping prediabetes or type 2diabetes.
Theremaywellbeanincreasedriskofmicrovascularcompli-
cations amongst these communities [8–13].
Native communities in north America have previously
been identiﬁed as having an increased risk of type 2 diabetes
[14]. While the risk of developing type 2 diabetes may vary
between various native-Canadian nations, many are exhibit-
ing an increased prevalence rate of type 2 diabetes [13, 15–
21]. Detailed studies of (Ojibwa-Cree native populations in
SandyLake,Ontario,Canada)haverevealedincreasedpreva-
lence rates of impaired glucose tolerance as well as type 2 di-
abetes [8, 10, 22]. Similar abnormalities have been noted in
(James Bay Cree in northern Qu´ ebec, Canada) [19].
Native Canadians have also been identiﬁed as having
increased morbidity and mortality associated with diabetes
with a greater impact on quality of life and a strong associa-
tion between diabetes, hypertension, heart disease, and sight
impairment [9]. Renal disease is also more prominent with
an increased prevalence rate of diabetic end-stage renal dis-
ease evident in native Canadians [23–26].
There are only a limited number of studies related to di-
abetic retinopathy in native populations. In Canada partic-
ularly, many native populations are in remote areas and ex-
t e n s i v es t u d i e sh a v ep r o v e nt ob ed i ﬃcult. Increased vascu-
lar complications, including diabetic retinopathy, have been
noted in the James Bay Cree and other native populations
[24, 25, 27, 28]. Haﬀner et al. noticed an increase preva-
lence rate of diabetic retinopathy in Mexican-American di-
abetic subjects compared to Caucasian diabetic subjects re-
viewed in (Wisconsin Epidemiologic Study of Diabetes, Wis,
USA) suggesting an ethnicity eﬀect on the risk of develop-
ing diabetic retinopathy [29]. Studies of the Pima Indians
have shown a similar increase in prevalence rates [30]. An
urban study, however, carried out in the native population
in Vancouver, showed that visual disability was nine times
greater than in the general Canadian population but diabetic
retinopathy was not a major cause of that visual loss [31].
Various risk factors have been identiﬁed as leading to
an increased incidence of diabetic retinopathy. These in-
clude glycemic control [4, 5, 32–35], elevated blood pres-
sure [3, 33, 36–38], abnormal lipids [39, 40], and duration
of diabetes [41]. It is thought that native Canadians may
exhibit higher prevalence rates of these risk factors, com-
pared to nonnative individuals. Detailed studies of native-
north Americans have revealed high prevalence rates of these
risk factors. A review of the Sandy Lake community demon-
strated high prevalence rates of vascular complications and
associated risk factors [8, 11]. Studies of other native Cana-
dian communities have revealed similar results [18, 42, 43].
The prevalence data from the Southern Alberta Study
of Diabetic Retinopathy (SASDR) provides a unique op-
portunity to review prevalence rates of diabetic retinopa-
thy, severity and the potential associated risk factors for the
development of retinopathy directly between insulin and
noninsulin using type 2 diabetic native and nonnative sub-
jects.
As can be seen from the data presented, there were no
diﬀerencesinprevalenceratesofretinopathybetweenthena-
tive and nonnative groups. Native subjects with retinopathy,4 Experimental Diabetes Research
Table 5: Risk factors for diabetic retinopathy.
Factor Observations Average Standard deviation P
Native Nonnative Native Nonnative Native Nonnative
A1c 224 2010 7.52 7.15 2.0 1.78 .008
BP-S mm/Hg 228 2010 129 130 21.59 19.07 .3611
BP-D mm/Hg 228 2010 78 75 10.27 10.11 .0025
Total-Cholesterol mmol/L 225 2011 5.4311 5.5454 1.12 1.32 .0274
HDL-C mmol/L 225 2007 1.1748 1.056 0.37 0.32 <.0005
Duration years 221 1981 8.26 9.08 7.13 8.42 .164
Table 6: No retinopathy and associated risk factors.
Ret1 Observations Average Standard deviation P
Native Nonnative Native Nonnative Native Nonnative
A1c 134 1205 7.20 6.85 1.89 1.67 .0455
BP-S mm/Hg 137 1205 125 127 18.3 17.8 .1262
BP-D mm/Hg 137 1205 77 75 9.2 10 .0544
Total-Cholesterol mmol/L 135 1206 5.323 5.533 1.02 1.32 .0733
HDL-C mmol/L 135 1202 1.182 1.055 0.385 0.312 .003
Duration years 133 1190 5.962 7.086 5.95 7.65 .1015
Table 7: Background retinopathy and associated risk factors.
Ret2 Observations Average Standard deviation P
Native Nonnative Native Nonnative Native Nonnative
A1c 45 551 7.74 7.37 1.77 1.67 .1596
BP-S mm/Hg 45 551 131 133 20.5 19.9 .662
BP-D mm/Hg 45 551 80 76 11.3 9.9 .01
Total-Cholesterol mmol/L 45 551 5.282 5.513 1.01 1.26 .2291
HDL-C mmol/L 45 551 1.178 1.076 0.391 0.335 .0524
Duration years 40 535 8.6 11.215 5.56 8.51 .0564
Table 8: Preproliferative retinopathy and associated risk factors.
Ret3 Observations Average Standard deviation P
Native Nonnative Native Nonnative Native Nonnative
A1c 33 174 8.03 8.17 2.0 1.89 .7006
BP-S mm/Hg 33 174 77 77 11.4 10.1 .965
BP-D mm/Hg 33 174 133 137 26.3 20.6 .4216
Total-Cholesterol mmol/L 33 174 5.376 5.731 1.6 1.53 .2254
HDL-C mmol/L 33 174 1.166 1.022 0.302 0.297 .0119
Duration years 33 174 13.939 13.362 6.99 8.24 .7064
Table 9: Proliferative retinopathy and associated risk factors.
Ret4 Observations Average Standard deviation P
Native Nonnative Native Nonnative Native Nonnative
A1c 12 80 8.76 7.88 2.55 1.55 .2596
BP-S mm/Hg 13 80 147 136 32.4 20.7 .2577
BP-D mm/Hg 13 80 80 76 13.8 12.7 .2593
Total-Cholesterol mmol/L 12 80 5.7108 5.546 1.17 1.31 .6828
HDL-C mmol/L 12 80 1.113 1.01 0.338 0.249 .208
Duration years 13 80 16.769 15.4 9.2 9.25 .6217Stuart A. Ross et al. 5
however, tended to have more advanced changes of retinopa-
thy compared to the nonnative subjects.
When assessing the role of potential risk factors for the
development or progression of diabetic retinopathy, again,
there were only few and minor diﬀerences between native
and nonnative subjects. Both native and nonnative subjects
with more severe presentation of diabetic retinopathy tended
to have higher levels of A1c compared to those with less se-
vere forms of retinopathy. Signiﬁcantly higher levels of A1c
were observed only in native subjects who did not exhibit
retinopathy. A1c was not statistically signiﬁcant for patients
with some form of retinopathy. Native subjects tended to
have lower total-cholesterol and higher HDL-C values com-
pared to nonnative groups although these diﬀerences were
small. Duration of diabetes, which is recognized as a ma-
jor risk factor for the development and severity of diabetic
retinopathy, was not signiﬁcantly diﬀerent between native
and nonnative subjects.
Of interest are the diﬀerences in prevalence and severity
of diabetic retinopathy in the southern Alberta native sub-
jects compared to those from the detailed Sandy Lake study
[11]. The prevalence rates of retinopathy were far higher in
thesouthernAlbertacohortandsimilartothoseidentiﬁedin
the Wisconsin Eye Studies [44].
These data indicate that ethnicity does play a signiﬁcant
role in the development and severity of diabetic retinopathy
but potential risk factors that may accelerate the develop-
ment of retinopathy are not signiﬁcantly diﬀerent between
native and nonnative groups.
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